Nebivolol/Hydrochlorothiazide Zentiva (Hydrochlorothiazide, Nebivolol)

Nebivolol/Hydrochlorothiazide, the active ingredient in Nebivolol/Hydrochlorothiazide Zentiva, is a beta‑blocker / thiazide diuretic presented as an oral tablet for oral use. The formulation combines a selective β1‑adrenergic antagonist with a thiazide diuretic to provide complementary blood‑pressure control. It treats hypertension in adult patients by lowering elevated blood pressure and reducing cardiovascular risk.

GNH USA supplies Nebivolol/Hydrochlorothiazide Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebivolol/Hydrochlorothiazide is indicated for the management of hypertension, a condition characterized by chronically elevated arterial pressure.

- Essential hypertension: reduces systolic and diastolic blood pressure to target levels. - Secondary hypertension: assists in blood‑pressure control when underlying causes contribute to elevated pressure. - High cardiovascular‑risk patients: helps achieve recommended blood‑pressure goals to lower risk of cardiovascular events.

Nebivolol/Hydrochlorothiazide may cause a range of adverse reactions, which are classified by frequency.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate pain often occurring early in therapy. - Fatigue: feeling of tiredness or reduced energy. - Increased urination: due to the diuretic component.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure that may cause fainting. - Electrolyte disturbances: notably low potassium or sodium levels. - Acute pancreatitis: inflammation of the pancreas requiring immediate medical attention. - Allergic reactions: rash, itching, swelling, or difficulty breathing.

Before prescribing Nebivolol/Hydrochlorothiazide, clinicians should consider several safety precautions.

- Blood pressure monitoring: check for excessive hypotension after initiation or dose changes. - Renal function assessment: evaluate creatinine clearance, especially in patients with chronic kidney disease. - Electrolyte surveillance: monitor potassium and sodium levels due to diuretic effect. - Diabetes management: observe for alterations in blood glucose control. - Avoid abrupt discontinuation: taper to prevent rebound hypertension. - Store at room temperature: keep in the original container, protect from moisture and light.

Nebivolol/Hydrochlorothiazide can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): may increase nebivolol plasma concentrations. - Lithium: concurrent use can raise lithium levels and risk toxicity. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may reduce the diuretic effect and impair renal function.

Moderate Interactions (Monitor Closely): - Other antihypertensives (e.g., ACE inhibitors, ARBs): may cause additive blood‑pressure lowering. - Additional diuretics: increase risk of electrolyte imbalance. - Beta‑agonists (e.g., albuterol): may diminish bronchodilator response.